Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study

Accumulating evidence has demonstrated that both SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. Combination therapy with SGLT2i and GLP1Ra is commonly used in patients with type 2 diabetes (T2D). We previously reported...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Yoshimi Muta, Kazuo Kobayashi, Masao Toyoda, Atsuhito Tone, Daisuke Suzuki, Daisuke Tsuriya, Hideo Machimura, Hidetoshi Shimura, Hiroshi Takeda, Hisashi Yokomizo, Kei Takeshita, Keiichi Chin, Keizo Kanasaki, Kouichi Tamura, Masaaki Miyauchi, Masuo Saburi, Miwa Morita, Miwako Yomota, Moritsugu Kimura, Nobuo Hatori, Shinichi Nakajima, Shun Ito, Shunichiro Tsukamoto, Takashi Murata, Takaya Matsushita, Takayuki Furuki, Takuya Hashimoto, Tomoya Umezono, Yuichi Takashi, Daiji Kawanami
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2024-03-01
Ráidu:	Frontiers in Pharmacology
Fáttát:	sodium-glucose cotransporter 2 inhibitors glucagon-like peptide 1 receptor agonists renal outcome combination therapy preceding drug diabetic kidney disease
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1358573/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!